A retrospective analysis revealed that elderly women with early stage triple negative breast cancer benefited from adjuvant radiation therapy after lumpectomy.
The European health regulators conditionally approved Blincyto, a treatment for acute lymphoblastic leukemia (ALL), a rare blood cancer.
Roche’s combination therapy for skin cancer received a positive opinion from the European Commission, bringing closer the approval of the drug for European patients.
The targeted drug nivolumab extended survival in patients with advanced kidney cancer whose disease has progressed on prior treatment, according to a new study.
The immunotherapy drug Opdivo extended survival rates in kidney cancer patients by more than two years, a new study reports.
The results of new study show that almost one-third of families of children with cancer face difficulties in meeting food, housing and energy needs during treatment.
The combination of trifluridine and tipiracil, once rejected because of its high toxicity levels, has being approved by the DFA for the treatment of colorectal cancer.
A new analysis of 70 existing studies revealed that in patients diagnosed with cancer, physical activity extended survival rates.
The emotional state of a breast cancer patient who undergoes surgical intervention is found to be a risk factor for acute postoperative pain, a new study reveals.
A new study reveals that for metastatic cancer patients, an individualized approach would be beneficial to select the most appropriate and effective therapy.
Advaxis’ experimental cancer vaccine improved survival rates in patients of cervical cancer compared with standard therapy, the company announced.
A randomized trials showed that the added to chemotherapy inhibitor cetuximab failed to improve survival in patients with advanced non-small cell lung cancer.
Combining traditional chemotherapy with immunotherapy is safe for patients with advanced small cell lung cancer and non-small cell lung cancer, a new study reveals.
A new long-term study showed that treatment was unnecessary for the majority of older men diagnosed with low-risk prostate cancer and under an active surveillance scheme.
Tesaro’s Varubi got approved by the FDA for the prevention of delayed phase chemotherapy-induced nausea and vomiting.
Immunotherapy drug ipilimumab benefited only melanoma patients with a specific type of tumor-produced antigens, a new study reveals.
Two immunotherapies, Opdivo and Yervoy can be safely and effectively combined to treat patients with previously untreated lung cancer, an early-stage study shows.
The American Society of Clinical Oncology created a guideline to help doctors choose the best therapies for patients with advanced non-small cell lung cancer.
Prostate cancer patients with relatively unaggressive tumors survived without surgery or radiation, due to an active surveillance program, a new study proves.
Acupuncture may offer relief for breast cancer patients against hot flashes, particular common when taking estrogen-taking therapies, according to a new study.
Beta-blockers proved to be beneficial for ovarian cancer patients as they doubled survival, showed a clinical study of 1,425 patients.
Daratumumab, a breakthrough antibody therapy, showed very promising results in drug-resistant patients with multiple myeloma whose disease had relapsed.
Childhood cancer survivors are at a greater risk of suffering a stroke. These findings will lead to secondary stroke prevention strategies in high-risk patients.
Senior oncology patients often use alternative medications together with their cancer treatment without knowing the potential drug-drug interactions.
Breast cancer patients often face difficulties in losing weight after treatment. Researchers now report that these women can lose weight with a personalized intervention.
Young women with breast cancer may refuse to be treated with the effective treatment, tamoxifen, due to the drug’s side effects on fertility.
European regulators have accepted the marketing authorization application for ixazomib, an investigational oral drug meant to treat relapsed/refractory myeloma patients.
Researchers have discovered a method to identify which myeloma patients are at a greater risk of relapse and premature death.
The combination of olaparib (Lynparza) and paclitaxel improved overall survival in high-risk gastric cancer patients, a new study revealed.
A new study reveals the specific structural and continuous brain changes resulting from standard radiation and chemotherapy in patients with glioblastoma.